Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Volasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 17/20 | 1.00 |
| ▸ | BRD4 | O60885 | 12/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 4/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 4/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 1.00 |
| ▸ | PDXK | O00764 | 2/20 | 1.00 |
| ▸ | NEK3 | P51956 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
| ▸ | WEE1 | P30291 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.64 |
| ▸ | CLK2 | P49760 | 3/20 | 0.64 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.64 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.64 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.64 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.64 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.64 |
| ▸ | PRKCG | P05129 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Volasertib SCHEMBL2169101 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL16984415 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL30753526 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL9888052 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL18636896 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL738946 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL29363620 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL18636919 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL21916558 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL29644957 | 0.99 | PLK1 (0.99) | PLK1BRD4PLK3PTK2BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129430-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | VeraVerse Co., Ltd. (KR) | 2025-04-24 | — | — | US | claimed |
| EP-4442840-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | Veraverse Co., Ltd. (KR) | 2024-10-09 | — | — | EP | claimed |
| WO-2023085716-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | 연세대학교 산학협력단 | 2023-05-19 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | BRYET US, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250129430-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | VeraVerse Co., Ltd. (KR) | 2025-04-24 | — | — | US | disclosed |
| WO-2025074271-A1 | MYT1 INHIBITORS FOR THE TREATMENT OF CANCERS HARBORING REPLICATION STRESS MUTATIONS | REPARE THERAPEUTICS INC. (CA) | 2025-04-10 | — | — | WO | disclosed |
| EP-4442840-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | Veraverse Co., Ltd. (KR) | 2024-10-09 | — | — | EP | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| CN-117045660-A | Application of PLK1 inhibitor in preparation of medicines for relieving kidney fibrosis | 南京市儿童医院 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023085716-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | 연세대학교 산학협력단 | 2023-05-19 | — | — | WO | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9567641-B2 | Combination therapy for the treatment of cancer using an anti-C-met antibody | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-02-14 | — | — | US | disclosed |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160024051-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | INFINITY PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150010575-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING AN ANTI-C-MET ANTIBODY | GEORGETOWN UNIVERSITY | 2015-01-08 | — | — | US | disclosed |
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | MSN, CD47, CTTN | PLK1 304/4885BRD4 4644/4885PLK3 3751/4885 |
| US-20150010575-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING AN ANTI-C-MET ANTIBODY | MET, HGF, HGFAC | PLK1 1994/4885BRD4 2671/4885PLK3 3318/4885 |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, PIK3CG, PIK3CD | PLK1 276/4885BRD4 1751/4885PLK3 363/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | PLK1 2955/4885BRD4 1044/4885PLK3 3287/4885 |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-20160024051-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | PIK3CA, PIK3CD, JAK2 | PLK1 57/4885BRD4 1022/4885PLK3 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.